Call for Abstracts

Interested participants are invited to submit abstracts on topics related to hereditary breast and ovarian cancer.

Submissions are welcome from all disciplines. Specific topic categories are listed below. Abstracts may be in English or French and must not exceed 300 words.

Abstracts may be submitted for Oral or Poster presentation.

All abstracts received by the submission deadline will be reviewed. Should a submission for oral presentation not be accepted as an oral, it will then automatically be considered for poster presentation.

Oral: An oral presentation describing a project or activity that falls within one of the topics listed below. Proffered paper oral presentations are limited to 10 minutes and presenters will participate with the invited faculty in a Question & Answer period at the end of the Session.

Poster: A visual presentation describing a project or activity. Posters must be designed to fit the predetermined guidelines. As much as possible, authors are expected to be present with their poster during breaks to answer questions from participants. No audiovisual support is provided for poster presentations.

  Deadline for Oral Abstract Submission:

  December 8, 2017

  Deadline for Poster Abstract Submission:

  January 19, 2018

Publication of Abstracts

All accepted abstracts will be published in the Symposium Book of Abstracts. In addition, most of the abstracts will be published in Current Oncology in online only format. Current Oncology is the only peer-reviewed journal covering Canadian oncologic practice.

Encore Abstracts

The Symposium will accept "Encore" abstracts. However, these will not be published in Current Oncology.

"Trials in Progress" Abstracts

The Symposium will accept "Trials in progress" abstracts. However, if submitting for an Oral presentation, there must be data.

How to Submit an Abstract:

Please click on the link supplied below for the Online Abstract Submission Form. You will need to sign up to our submission system by supplying your email address and a password. There is no paper version of this form. Abstracts not prepared correctly will NOT be considered.

Abstract categories include:

  • Biology of hereditary cancers
  • BRCA1/2 mutations, variants of unknown clinical significance and databases
  • Clinical issues for management
  • Education
  • Ethics and legal issues
  • Genome-wide approaches to identify new genetic risk factors
  • Molecular pathology and genetic analyses of BRCA1/2-associated cancers
  • Non-BRCA1/2 genetic factors associated with cancer risk
  • Psycho-oncology
  • Risk assessment and genetic counselling issues